News
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
Zacks Investment Research on MSN6h
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?Edwards Lifesciences EW is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned for continued ...
Edwards' Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data. May 17, 2023 04:25 AM Eastern Daylight Time. NEWBURY, ...
AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards' bioprosthetic surgical aortic valve ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback